01 8Brilinta/Brilique
02 2Brilinta/Brilique
Main Therapeutic Indication : Cardiovascular Diseases
Currency : USD
2020 Revenue in Millions : 1,593
2019 Revenue in Millions : 1,581
Growth (%) : 1
Main Therapeutic Indication : Cardiovascular Diseases
Currency : USD
2021 Revenue in Millions : 1,472
2020 Revenue in Millions : 1,593
Growth (%) : -8
Main Therapeutic Indication : Cardiology/Vascular Diseases
Currency : USD
2022 Revenue in Millions : 1,358
2021 Revenue in Millions : 1,472
Growth (%) : -8
Main Therapeutic Indication : Cardiology/Vascular Diseases
Currency : USD
2023 Revenue in Millions : 1,324
2022 Revenue in Millions : 1,358
Growth (%) : -3
Main Therapeutic Indication : Cardiovascular
Currency : USD
2015 Revenue in Millions : 476
2014 Revenue in Millions : 619
Growth (%) : 30%
Main Therapeutic Indication : Cardiovascular Diseases
Currency : USD
2017 Revenue in Millions : 1,079
2016 Revenue in Millions : 839
Growth (%) : 29
Main Therapeutic Indication : Cardiovascular
Currency : USD
2014 Revenue in Millions : 68.20%
2013 Revenue in Millions :
Growth (%) :
Main Therapeutic Indication : Cardiovascular Diseases
Currency : USD
2018 Revenue in Millions : 1,321
2017 Revenue in Millions : 1,079
Growth (%) : 22%
Main Therapeutic Indication : Cardiovascular Diseases
Currency : USD
2016 Revenue in Millions : 839
2015 Revenue in Millions : 619
Growth (%) : 36
Main Therapeutic Indication : Cardiovascular Diseases
Currency : USD
2019 Revenue in Millions : 1,581
2018 Revenue in Millions : 1,321
Growth (%) : 20
LOOKING FOR A SUPPLIER?